Tranexamic acid
Accession Number
DB00302  (APRD01270, EXPT00508)
Small Molecule

Antifibrinolytic hemostatic used in severe hemorrhage.

  • Acide tranéxamique
  • ácido tranexámico
  • Acidum tranexamicum
  • Tranexamic acid
  • Tranexamsaeure
  • Tranexmic acid
  • Tranhexamic acid
  • Trans AMCHA
  • trans-4-(Aminomethyl)cyclohexanecarboxylic acid
  • trans-4-aminomethylcyclohexane-1-carboxylic acid
  • trans-Amcha
  • trans-Tranexamic acid
External IDs
CL 65336 / CL-65336 / RP-18429
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CyklokapronInjection, solution100 mg/1mLIntravenousPharmacia and Upjohn Company LLC1986-12-30Not applicableUs
CyklokapronTablet500 mg/1OralPharmacia and Upjohn Company2006-01-042006-01-04Us
Cyklokapron 100 mg/mlSolutionIntravenousPfizer Canada Ulc1995-12-31Not applicableCanada
Cyklokapron 500 mgTabletOralPfizer Canada Ulc1995-12-31Not applicableCanada
Erfa-tranexamicSolutionIntravenousErfa Canada 2012 Inc2017-07-31Not applicableCanada
LystedaTablet650 mg/1OralFerring Pharmaceuticals Inc.2010-05-17Not applicableUs
LystedaTablet650.0 mgOralFerring PharmaceuticalsNot applicableNot applicableCanada
LystedaTablet650 mg/1OralFerring Pharmaceuticals2010-05-172015-12-31Us
LystedaTablet650 mg/1OralXanodyne Pharmaceuticals2010-05-172010-05-17Us
Tranexamic Acid In Sodium ChlorideInjection, solution10 mg/1mLIntravenousExela Pharma Sciences, LLC2019-06-01Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Gd-tranexamic AcidSolutionIntravenousGenmed A Division Of Pfizer Canada UlcNot applicableNot applicableCanada
Gd-tranexamic AcidTabletOralGenmed A Division Of Pfizer Canada Ulc2014-03-07Not applicableCanada
Mar-tranexamic AcidTabletOralMarcan Pharmaceuticals Inc2020-06-04Not applicableCanada
Tranexamic AcidInjection, solution100 mg/1mLIntravenousX-GEN Pharmaceuticals, Inc.2012-05-18Not applicableUs
Tranexamic AcidInjection, solution100 mg/1mLIntravenousACELLA PHARMACEUTICALS2014-02-11Not applicableUs
Tranexamic AcidInjection, solution1 g/10mLIntravenousHeritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.2014-08-13Not applicableUs
Tranexamic AcidInjection, solution100 mg/1mLIntravenousAthenex Pharmaceutical Division, Llc.2017-03-27Not applicableUs
Tranexamic AcidInjection, solution1 g/10mLIntravenousHeritage Pharmaceuticals Inc.2014-08-13Not applicableUs
Tranexamic AcidInjection, solution100 mg/1mLIntravenousA-S Medication Solutions2012-05-18Not applicableUs
Tranexamic AcidInjection, solution100 mg/1mLIntravenousA-S Medication Solutions2019-09-30Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Pure Whitenol SerumCream0.05 mg/50mLTopicalSkin M.D. Korea2015-02-01Not applicableUs
Skinmd Laboratories Pure Whitenol SerumCream0.05 g/50mLTopicalReviresco Co., Ltd.2017-12-01Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Skinmd Laboratories Pure Whitenol IntensiveTranexamic acid (0.02 g/10mL) + Adenosine (0.004 g/10mL)CreamTopicalReviresco Co., Ltd.2017-12-01Not applicableUs
SKINMD LABORATORIES ReviTox blueTranexamic acid (0.001 g/10mL) + Adenosine (0.004 g/10mL)LiquidTopicalReviresco Co., Ltd.2017-12-01Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Pure Whitenol SerumTranexamic acid (0.05 mg/50mL)CreamTopicalSkin M.D. Korea2015-02-01Not applicableUs
Skinmd Laboratories Pure Whitenol IntensiveTranexamic acid (0.02 g/10mL) + Adenosine (0.004 g/10mL)CreamTopicalReviresco Co., Ltd.2017-12-01Not applicableUs
Skinmd Laboratories Pure Whitenol SerumTranexamic acid (0.05 g/50mL)CreamTopicalReviresco Co., Ltd.2017-12-01Not applicableUs
SKINMD LABORATORIES ReviTox blueTranexamic acid (0.001 g/10mL) + Adenosine (0.004 g/10mL)LiquidTopicalReviresco Co., Ltd.2017-12-01Not applicableUs
International/Other Brands
Cyclo-F / Espercil / Femstrual / Rikavarin / Transamin / Transcam / Traxyl
CAS number
Average: 157.2102
Monoisotopic: 157.110278729
Chemical Formula
InChI Key
(1r,4r)-4-(aminomethyl)cyclohexane-1-carboxylic acid



For use in patients with hemophilia for short term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. It can also be used for excessive bleeding in menstruation, surgery, or trauma cases.

Associated Conditions

Tranexamic acid is an antifibrinolytic that competitively inhibits the activation of plasminogen to plasmin. Tranexamic acid is a competitive inhibitor of plasminogen activation, and at much higher concentrations, a noncompetitive inhibitor of plasmin, i.e., actions similar to aminocaproic acid. Tranexamic acid is about 10 times more potent in vitro than aminocaproic acid. Tranexamic acid binds more strongly than aminocaproic acid to both the strong and weak receptor sites of the plasminogen molecule in a ratio corresponding to the difference in potency between the compounds. Tranexamic acid in a concentration of 1 mg per mL does not aggregate platelets in vitro. In patients with hereditary angioedema, inhibition of the formation and activity of plasmin by tranexamic acid may prevent attacks of angioedema by decreasing plasmin-induced activation of the first complement protein (C1).

Mechanism of action

Tranexamic acid competitively inhibits activation of plasminogen (via binding to the kringle domain), thereby reducing conversion of plasminogen to plasmin (fibrinolysin), an enzyme that degrades fibrin clots, fibrinogen, and other plasma proteins, including the procoagulant factors V and VIII. Tranexamic acid also directly inhibits plasmin activity, but higher doses are required than are needed to reduce plasmin formation.

Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more

Absorption of tranexamic acid after oral administration in humans represents approximately 30 to 50% of the ingested dose and bioavailability is not affected by food intake.

Volume of distribution
  • 9 to 12 L
Protein binding

The plasma protein binding of tranexamic acid is about 3% at therapeutic plasma levels and seems to be fully accounted for by its binding to plasminogen (does not bind serum albumin).


Only a small fraction of the drug is metabolized (less than 5%).

Route of elimination

Urinary excretion is the main route of elimination via glomerular filtration.

Half life

Biological half-life in the joint fluid is about 3 hours.

  • 110 - 116 mL/min

Oral LD50 in mice is >10 gm/kg. Symptoms of overdosage may be nausea, vomiting, orthostatic symptoms and/or hypotension.

Affected organisms
  • Humans and other mammals
Tranexamic Acid Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available


Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Albutrepenonacog alfaTranexamic acid may increase the thrombogenic activities of Albutrepenonacog alfa.
Alpha-1-proteinase inhibitorAlpha-1-proteinase inhibitor may increase the thrombogenic activities of Tranexamic acid.
Aminocaproic acidTranexamic acid may increase the thrombogenic activities of Aminocaproic acid.
Aminomethylbenzoic acidTranexamic acid may increase the thrombogenic activities of Aminomethylbenzoic acid.
Andexanet alfaTranexamic acid may increase the thrombogenic activities of Andexanet alfa.
Anti-inhibitor coagulant complexTranexamic acid may increase the thrombogenic activities of Anti-inhibitor coagulant complex.
Antihemophilic Factor (Recombinant), PEGylatedTranexamic acid may increase the thrombogenic activities of Antihemophilic Factor (Recombinant), PEGylated.
Antihemophilic factor humanTranexamic acid may increase the thrombogenic activities of Antihemophilic factor human.
Antihemophilic factor, human recombinantTranexamic acid may increase the thrombogenic activities of Antihemophilic factor, human recombinant.
AprotininTranexamic acid may increase the thrombogenic activities of Aprotinin.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
  • Take with or without food.


Synthesis Reference

Noa Zerangue, Bernd Jandeleit, Yunxiao Li, "Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use." U.S. Patent US20070027210, issued February 01, 2007.

General References
Not Available
External Links
Human Metabolome Database
PubChem Compound
PubChem Substance
Therapeutic Targets Database
PDBe Ligand
RxList Drug Page Drug Page
ATC Codes
B02AA02 — Tranexamic acid
AHFS Codes
  • 20:28.16 — Hemostatics
PDB Entries
1b2i / 1ceb / 5v3c / 6nmb
Download (63.5 KB)

Clinical Trials

Clinical Trials
0CompletedOtherKnee Prosthesis1
0Not Yet RecruitingPreventionInduction of intra-operative hypotension1
0Not Yet RecruitingTreatmentTendon Injury - Hand1
0RecruitingPreventionBlood Loss,Surgical / Hysterectomy1
0RecruitingPreventionOpen Posterior Thoracolumbar Spinal Fusion Procedure1
0RecruitingTreatmentPelvic Mass1
1Active Not RecruitingPreventionIleus / Tissue Adhesions1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentHemorrhage/Blood Loss During Myomectomies / Leiomyomas1
1RecruitingOtherHealthy Volunteer Study1
1RecruitingTreatmentTherapeutic Efficacy1
1Unknown StatusPreventionDegenerative Arthritis1
1Unknown StatusTreatmentAcute Blood Loss Anemia / Osteoarthritis, Hip1
1WithdrawnTreatmentHeavy Menstrual Bleeding1
1, 2CompletedOtherTraumatic haemorrhage1
1, 2CompletedPreventionAdolescent Idiopathic Scoliosis (AIS)1
1, 2CompletedPreventionHemorrhage1
1, 2CompletedPreventionPostpartum Haemorrage Sever Bleeding After Delivery1
1, 2Not Yet RecruitingPreventionPostpartum Haemorrhage (PPH)1
1, 2RecruitingTreatmentChronic Subdural Hematomas1
1, 2RecruitingTreatmentHypermenorrhea1
1, 2RecruitingTreatmentPolytrauma / Traumatic haemorrhage1
1, 2SuspendedPreventionCoagulation Defect; Acquired / Hemostatic Disorder / Pediatric Cancer / Thrombocytopenia1
1, 2Unknown StatusPreventionHemorrhage of Cesarean Section and/or Perineal Wound1
2Active Not RecruitingPreventionOsteoarthritis (OA)1
2Active Not RecruitingPreventionPostpartum Haemorrhage (PPH)1
2Active Not RecruitingTreatmentHemorrhage / Injuries, Brain / Wounds and Injuries1
2Active Not RecruitingTreatmentHemorrhage / Shock / Wounds and Injuries1
2CompletedPreventionBleeding / Surgical Wound1
2CompletedPreventionBlood Clots / Blood Loss / Osteoarthritis of the Knee / Transfusion Related Complications1
2CompletedPreventionBloodloss / Surgical Procedures, Operative1
2CompletedPreventionDegenerative Joint Disease1
2CompletedPreventionJoint Dysfunction1
2CompletedPreventionPostoperative Hemorrhages1
2CompletedPreventionPostpartum Haemorrhage (PPH)1
2CompletedSupportive CareBleeding1
2CompletedTreatmentAcute Blood Loss Anemia / Osteoarthritis of the Knee1
2CompletedTreatmentCerebral Hemorrhage / Stroke1
2CompletedTreatmentCurvature of Spine1
2CompletedTreatmentEpistaxis / Hereditary Haemorrhagic Telangiectasia (HHT)1
2CompletedTreatmentOsteoarthritis of the Knee1
2CompletedTreatmentTraumatic Brain Injury (TBI)1
2Not Yet RecruitingPreventionHigh Risk Pregnancies / Pregnancy, High-Risk1
2Not Yet RecruitingTreatmentCOVID-19 Pneumonia / Novel Coronavirus Infectious Disease (COVID-19)1
2Not Yet RecruitingTreatmentIntervertebral Disc Degeneration1
2Not Yet RecruitingTreatmentNovel Coronavirus Infectious Disease (COVID-19)1
2RecruitingPreventionBlood Loss,Surgical1
2RecruitingPreventionBlood Loss,Surgical / Hip Fracture / Postoperative Complications1
2RecruitingPreventionBronchoscopy Biopsy1
2RecruitingTreatmentAnterior Cruciate Ligament Reconstruction1
2RecruitingTreatmentCerebral Hemorrhage1
2RecruitingTreatmentCerebral Hemorrhage / Stroke1
2RecruitingTreatmentHematological Malignancies Treated With Intensive Chemotherapy1
2RecruitingTreatmentHip Fracture1
2RecruitingTreatmentIntraoperative Bleeding1
2RecruitingTreatmentNovel Coronavirus Infectious Disease (COVID-19)1
2RecruitingTreatmentOsteoarthritis of the Knee1
2RecruitingTreatmentPost Partum Hemorrhage1
2TerminatedPreventionPostpartum Haemorrhage (PPH)1
2TerminatedTreatmentHypotension / Illness, Critical / Sepsis / Shock1
2TerminatedTreatmentNon-idiopathic Scoliosis1
2TerminatedTreatmentPost Operative Blood Loss1
2TerminatedTreatmentShock, Septic1
2TerminatedTreatmentTotal Knee Arthroplasty (TKA)1
2, 3Active Not RecruitingPreventionBlood Loss / Fibrinolysis; Hemorrhage / Post Partum Hemorrhage1
2, 3Active Not RecruitingTreatmentSubarachnoid Hemorrhage1
2, 3CompletedPreventionPostpartum Haemorrhage (PPH)1
2, 3CompletedTreatmentAdverse Effects of Medical Drugs / Effect of Drugs / Tranexamic Acid Adverse Reaction1
2, 3CompletedTreatmentBlood Loss,Surgical1
2, 3CompletedTreatmentBlood Loss,Surgical / Complications; Arthroplasty / Intraoperative Complications / Shoulder Joint Disease1
2, 3CompletedTreatmentIntraoperative Bleeding / Osteoarthritis (OA)1
2, 3Not Yet RecruitingTreatmentSpinal Deformities / Spinal Injuries1
2, 3RecruitingPreventionCancer, Bladder1
2, 3RecruitingPreventionPlacenta Previa1
2, 3RecruitingTreatmentAdult Spinal Deformity1
2, 3RecruitingTreatmentCerebral Hemorrhage1
2, 3RecruitingTreatmentChronic Subdural Hematomas1
2, 3RecruitingTreatmentPostinflammatory Hyperpigmentation1
2, 3Unknown StatusTreatmentHepatocellular Cancer / Malignant Neoplasm of Colon / Malignant Neoplasm of Pancreas / Malignant Neoplasm of Stomach1
3Active Not RecruitingPreventionBlood Loss, Postoperative / Blood Loss,Surgical / Osteoarthritis (OA)1
3Active Not RecruitingPreventionPost Partum Hemorrhage1
3Active Not RecruitingPreventionThrombocytopenia1
3Active Not RecruitingTreatmentAcetabular Fractures1
3Active Not RecruitingTreatmentPostpartum Haemorrhage (PPH)1
3Active Not RecruitingTreatmentShock, Hemorrhagic / Trauma Injury1
3CompletedDiagnosticBlood Loss1
3CompletedOtherNeoplasms, Hematologic1
3CompletedPreventionAnemia / Hip Fracture1
3CompletedPreventionAtherosclerotic Disease / Postoperative Hemorrhages1
3CompletedPreventionCoronary Artery Disease (CAD)1
3CompletedPreventionImmediate Postpartum Hemorrhage1
3CompletedPreventionKnee Arthropathy1
3CompletedPreventionObstetrical Hemorrhage1
3CompletedPreventionPlacenta Previa1
3CompletedPreventionPostpartum Haemorrhage (PPH)1
3CompletedSupportive CareBleeding1
3CompletedTreatmentAbdominal Aortic Aneurysms (AAA) / Blood Transfusion Requirements1
3CompletedTreatmentBlood Loss2
3CompletedTreatmentBlood Loss After a Total Hip Replacement1
3CompletedTreatmentBlood Loss / Hip Fracture1
3CompletedTreatmentGastrointestinal Bleeding1
3CompletedTreatmentGeneral Surgery / Malignancies / Tumour1
3CompletedTreatmentHeavy Menstrual Bleeding / Hypermenorrhea3
3CompletedTreatmentHereditary Angioedema1
3CompletedTreatmentHereditary Haemorrhagic Telangiectasia (HHT) / Osler-Rendu Disease1
3CompletedTreatmentHip Fracture1
3CompletedTreatmentInjuries, Brain1
3CompletedTreatmentNeoplasms, Head and Neck1
3CompletedTreatmentOsteoarthritis (OA)1
3CompletedTreatmentPostpartum Haemorrhage (PPH)1
3CompletedTreatmentSpine Surgery1
3CompletedTreatmentSurgery, Cardiac1
3CompletedTreatmentTraumatic Brain Injury (TBI)1
3CompletedTreatmentTraumatic haemorrhage1
3Enrolling by InvitationTreatmentFusion of Spine (Disease)1
3Enrolling by InvitationTreatmentOther Fusion of Spine, Lumbar Region / Scoliosis1
3Not Yet RecruitingBasic ScienceBleeding / Transfusion Related Complications1
3Not Yet RecruitingOtherNeoplasms, Hematologic1
3Not Yet RecruitingPreventionAbnormal Uterine Bleeding / Fibroid Uterus / Myoma;Uterus1
3Not Yet RecruitingPreventionLeiomyomas / Surgical Blood Loss1
3Not Yet RecruitingPreventionPostpartum Haemorrhage (PPH) / Tranexamic Acid1
3Not Yet RecruitingPreventionPostpartum Haemorrhage (PPH) / Von Willebrand Diseases1
3Not Yet RecruitingPreventionUterine Hemorrhage1
3Not Yet RecruitingSupportive CareCancer of the Bone / Limb Salvage1
3Not Yet RecruitingTreatmentAbnormal Uterine Bleeding1
3Not Yet RecruitingTreatmentBrain Injuries,Traumatic1
3Not Yet RecruitingTreatmentBrain Injuries,Traumatic / Hemorrhage / Trauma Injury / Wounds and Injuries1
3Not Yet RecruitingTreatmentChloasma / Melanosis / Melasma1
3Not Yet RecruitingTreatmentPostpartum Haemorrhage (PPH)1
3RecruitingPreventionGeneral Surgery / Peri-operative Hemorrhage or Hematoma / Retrognathism1
3RecruitingPreventionHemorrhage / Labor and Delivery / Obstetrical Complications1
3RecruitingPreventionIntrapartum - Moderate and Severe Anaemia1
3RecruitingPreventionPelvic Organ Prolapse (POP)1
3RecruitingPreventionPost Operative Hemorrhage1
3RecruitingPreventionPost Partum Hemorrhage1
3RecruitingPreventionPostpartum Haemorrhage (PPH)1
3RecruitingPreventionShock, Hemorrhagic1
3RecruitingSupportive CareHematopoietic Stem Cell Transplantation (HSCT) / Hemorrhage / Neoplasms, Hematologic1
3RecruitingTreatmentAcute Coagulopathy / Wounds and Injuries1
3RecruitingTreatmentAnemia / Hip Fracture Pathologic / Hip Fractures Pathologic1
3RecruitingTreatmentArterial thrombosis / Postoperative Hemorrhages / Thrombosis, Venous1
3RecruitingTreatmentBlood Loss,Surgical / Degenerative Lumbar Spinal Stenosis / Spinal Deformities1
3RecruitingTreatmentCerebral Hemorrhage / Hemorrhagic Stroke1
3RecruitingTreatmentChronic Sinus Disease / Polyps, Nasal1
3RecruitingTreatmentChronic Subdural Hematomas1
3RecruitingTreatmentGeneral Surgery / Malignancies / Tumour1
3RecruitingTreatmentHematoma, Subdural, Chronic1
3RecruitingTreatmentHip Fracture1
3RecruitingTreatmentIntra-Operative Injury - Other / Post Operative Hemorrhage / Tranexamic Acid1
3RecruitingTreatmentSepsis / Shock, Septic1
3RecruitingTreatmentTotal Blood Loss1
3RecruitingTreatmentTranexamic Acid1
3RecruitingTreatmentVon Willebrand Diseases1
3SuspendedTreatmentPostpartum Haemorrhage (PPH)1
3TerminatedTreatmentBlood Loss / Bone Tumour1
3TerminatedTreatmentFracture of Neck of Femur1
3Unknown StatusPreventionAllogeneic Blood Transfusions / Aortic Valve Replacement / Bleeding and Cardiac Surgery / Coronary Artery Bypass Grafting (CABG)1
3Unknown StatusTreatmentAcute Upper Gastrointestinal Hemorrhage1
3Unknown StatusTreatmentAstrocytomas / Gliomas / Meningiomas / Neoplasms / Neoplasms, Brain1
3Unknown StatusTreatmentHemoptisis1
3Unknown StatusTreatmentNeoplasms, Head and Neck1
3WithdrawnPreventionPlacenta Accreta1
4Active Not RecruitingTreatmentAnterior Cruciate Ligament Rupture1
4Active Not RecruitingTreatmentBlood Loss,Surgical1
4Active Not RecruitingTreatmentFracture of Femur1
4Active Not RecruitingTreatmentPrimary Total Hip Arthroplasty / Primary Total Knee Arthroplasty1
4CompletedNot AvailableHypermenorrhea1
4CompletedNot AvailableRevision Total Hip Arthroplasty (RTHA)1
4CompletedOtherComplication of Extracorporeal Circulation / Pediatric Cardiac Surgery1
4CompletedPreventionAdenoidectomy / Tonsillectomy / Tranexamic Acid1
4CompletedPreventionBiliary Tract Surgical Procedures / Colectomy / Gastric Resection / Oesophagectomy / Pancreatoduodenectomy1
4CompletedPreventionBleeding / Prostatectomy1
4CompletedPreventionBleeding / Surgical Blood Loss1
4CompletedPreventionBlood Loss,Surgical1
4CompletedPreventionCesarean Section / Placenta Accreta / Postpartum Haemorrhage (PPH) / Tranexamic Acid1
4CompletedPreventionFemoral Fractures1
4CompletedPreventionGynecologic Surgical Procedures / Hysterectomy / Tranexamic Acid1
4CompletedPreventionHemorrhage of Cesarean Section and/or Perineal Wound / Postpartum Haemorrhage (PPH)1
4CompletedPreventionHemorrhage of Cesarean Section and/or Perineal Wound / Postpartum Haemorrhage (PPH) / Uterine Atony1
4CompletedPreventionHip Fracture1
4CompletedPreventionIntraoperative Bleeding / Postoperative Edema1
4CompletedPreventionNeoplasms, Breast / Postoperative Hemorrhages / Seroma1
4CompletedPreventionOsteoarthritis of the Knee1
4CompletedPreventionPostoperative Hemorrhages / Postoperative pain1
4CompletedPreventionSurgical Blood Loss / Total Knee Arthroplasty (TKA)1
4CompletedSupportive CareSpinal Stenosis of Lumbar Region / Thoracic Spinal Stenosis1
4CompletedTreatmentAnterior Cruciate Ligament Reconstruction1
4CompletedTreatmentAntifibrinolytic Agents / Blood Transfusions / Fusion of Spine (Disease) / Hemorrhage1
4CompletedTreatmentAntifibrinolytic Agents / Emergency Department / Gastrointestinal Hemorrhage / Tranexamic Acid1
4CompletedTreatmentArthropathy of Hip / Arthropathy of Knee1
4CompletedTreatmentBlood Loss3
4CompletedTreatmentBlood Loss,Surgical1
4CompletedTreatmentBlood Loss,Surgical / Hip Replacement Surgery / Tranexamic Acid Adverse Reaction1
4CompletedTreatmentBlood Loss / Hip Arthritis / Knee Arthritis1
4CompletedTreatmentBlood Loss / Postoperative Blood Loss / Thromboembolic Complications1
4CompletedTreatmentBlood Loss / Surgery, Cardiac / Tranexamic Acid1
4CompletedTreatmentBunions / Foot and Ankle Surgeries1
4CompletedTreatmentC.Surgical Procedure; Cardiac1
4CompletedTreatmentCardiopulmonary Bypass / Hemorrhage1
4CompletedTreatmentCoronary Artery Occlusive Disease1
4CompletedTreatmentEpistaxis / Nasal Packing / Tranexamic Acid1
4CompletedTreatmentHeavy Menstrual Bleeding1
4CompletedTreatmentHemorrhage / Palate, Cleft1
4CompletedTreatmentHereditary Factor VIII Deficiency Disease With Inhibitor1
4CompletedTreatmentHip Arthropathy / Osteoarthritis (OA) / Shoulder Arthropathy1
4CompletedTreatmentHip Arthroplasty1
4CompletedTreatmentOsteoarthritis (OA)3
4CompletedTreatmentOsteoarthritis of the Knee1
4CompletedTreatmentOvarian Cancer1
4CompletedTreatmentPharmacological Action (PA)1
4CompletedTreatmentPost Partum Hemorrhage1
4CompletedTreatmentPostpartum Haemorrhage (PPH)1
4CompletedTreatmentUterine Hemorrhage1
4Enrolling by InvitationTreatmentSpine Surgery1
4Not Yet RecruitingOtherBleeding / Bruising Face / Swelling Lips & Face1
4Not Yet RecruitingPreventionBlood Loss Anemia / Blood Loss,Surgical1
4Not Yet RecruitingPreventionInjuries and Wounds / Postoperative Hemorrhages1
4Not Yet RecruitingPreventionMyomectomy2
4Not Yet RecruitingPreventionOsteoarthritis of the Knee3
4Not Yet RecruitingPreventionPostpartum Hemorrhage, Cesarean Section1
4Not Yet RecruitingPreventionHematomas / Seroma1
4Not Yet RecruitingPreventionTotal Blood Loss1
4Not Yet RecruitingSupportive CareGeneral Surgery1
4Not Yet RecruitingSupportive CareInjection site bruising1
4Not Yet RecruitingTreatmentAnaesthesia therapy / Bleeding / Gastrointestinal Complications / Healthcare Associated Infection / Infection Wound / Wound Infections1
4Not Yet RecruitingTreatmentDeep Vein Thrombosis / Myocardial Infarction / Pulmonary Embolism / Safety / Stroke1
4Not Yet RecruitingTreatmentMelasma1
4Not Yet RecruitingTreatmentMeningiomas1
4Not Yet RecruitingTreatmentMyomectomy1
4Not Yet RecruitingTreatmentOrthognathic Surgery / Tranexamic Acid1
4RecruitingPreventionArthroplasty, Replacement, Hip / Blood Loss,Surgical / Tranexamic Acid1
4RecruitingPreventionBleeding / Seizures / Surgical Blood Loss1
4RecruitingPreventionBreast Cancer / Hematoma Postoperative / Seroma Complicating A Procedure1
4RecruitingPreventionCesarean Section Complications1
4RecruitingPreventionHip Fracture / Surgical Blood Loss1
4RecruitingPreventionPostpartum Haemorrhage (PPH)1
4RecruitingPreventionRobotic-assisted Radical Prostatectomy1
4RecruitingPreventionTranexamic Acid Adverse Reaction1
4RecruitingSupportive CareBleeding Reduction1
4RecruitingTreatmentAnemia / Hip Fracture1
4RecruitingTreatmentBlood Loss1
4RecruitingTreatmentBurned / General Surgery / Tranexamic Acid / Wounds and Injuries1
4RecruitingTreatmentCalcium Nephrolithiasis / Staghorn Calculus1
4RecruitingTreatmentChronic Spontaneous Urticaria1
4RecruitingTreatmentComplications, Pregnancy / Hemorrhage1
4RecruitingTreatmentFracture of Neck of Femur1
4RecruitingTreatmentHeavy Menstrual Bleeding / Hypermenorrhea / Uterine Leiomyomas1
4RecruitingTreatmentHigh Tibial Osteotomy (HTO) / Osteotomy / Patello-femoral Ligament1
4RecruitingTreatmentHip Fracture1
4RecruitingTreatmentHip Replacement, Total1
4RecruitingTreatmentHomeostasis / Surgery, Cardiac1
4RecruitingTreatmentLiver Cirrhosis / Portal Hypertension / Upper Digestive Bleeding1
4RecruitingTreatmentMusculoskeletal Cancers / Soft Tissue Sarcoma (STS)1
4RecruitingTreatmentOsteoarthritis of the Knee1
4RecruitingTreatmentSubdural haematoma1
4RecruitingTreatmentSurgery, Colorectal1
4RecruitingTreatmentTooth Extractions1
4SuspendedTreatmentBlood Loss / Blood Transfusions1
4TerminatedPreventionBlood Loss / Hip Fracture1
4TerminatedTreatmentAnemia / Arthritis / Total Hip Arthroplasty (THA) / Total Knee Arthroplasty (TKA)1
4TerminatedTreatmentBleeding / Cranial Vault Surgery for Craniosynostosis / Craniosynostosis1
4TerminatedTreatmentBlood Loss1
4Unknown StatusDiagnosticBleeding1
4Unknown StatusPreventionPostoperative Blood Loss / Total Hip Arthroplasty (THA)1
4Unknown StatusSupportive CareBleeding1
4Unknown StatusTreatmentHemorrhage1
4Unknown StatusTreatmentNative Arteriovenous Fistula1
4Unknown StatusTreatmentOsteoarthritis of the Knee1
4WithdrawnPreventionFemur Surgery / Proximal Femur Surgery 1
4WithdrawnTreatmentBlood Loss Following Open Femur Fracture Surgery1
4WithdrawnTreatmentBlood Loss / Hip Fracture1
4WithdrawnTreatmentHeart Defect, Congenital / Whole Blood Platelet Aggregation Following Tranexamic Acid Administration or Placebo Administration1
Not AvailableActive Not RecruitingTreatmentMajor Surgery / Malignancies / Tranexamic Acid1
Not AvailableActive Not RecruitingTreatmentOsteoarthritis (OA)1
Not AvailableCompletedNot AvailableAcute Bacterial Exacerbation of Chronic Bronchitis (ABECB) / Acute Bacterial Sinusitis (ABS) / Acute Pyelonephritis / Adenovirus / Adjunct to general anesthesia therapy / Adrenal Insufficiency / Airway Swelling / Anaesthesia therapy / Anxiety / Anxiolysis / Autism, Early Infantile / Autistic Disorder / Bartonellosis / Benzodiazepine Withdrawal / Benzodiazepines / Bipolar Disorder (BD) / Bloodstream Infections / Bone and Joint Infections / Bradycardia / Brain Swelling / Bronchospasm / Brucellosis / Cardiac Arrest (CA) / Central Nervous System Infections / Cholera / Chronic Bacterial Prostatitis / Chronic Kidney Disease (CKD) / Community Acquired Pneumonia (CAP) / Complicated Urinary Tract Infection / Convulsions / Cytomegalovirus Retinitis / Decompensated Heart Failure / Drug hypersensitivity reaction / Dysrhythmia, Cardiac / Early-onset Schizophrenia Spectrum Disorders / Edema / Endocarditis / Epilepsies / Fibrinolytic Bleeding / Flu caused by Influenza / Gastroparesis / Gram-negative Infection / Gynaecological infection / Headache / Heart Failure / Heavy Menstrual Bleeding / Hemophilia / Herpes Simplex Virus / High Blood Pressure (Hypertension) / High Cholesterol / Hyperaldosteronism / Hyperlipidemias / Hypokalemia / Hypotension / Infantile Hemangiomas / Infection / Infection caused by staphylococci / Inflammatory Conditions / Inflammatory Reaction / Influenza Treatment or Prophylaxis / Inhalational Anthrax (Post-Exposure) / Insomnia / Intra-Abdominal Infections / Life-threatening Fungal Infections / Lower Respiratory Tract Infection (LRTI) / Meningitis, Bacterial / Methicillin Resistant Staphylococcus Aureus (MRSA) / Migraine / Muscle Spasms / Nausea / Neuromuscular Blockade / Neutropenia / Nosocomial Pneumonia / Opioid Addiction / Pain / Plague / Pneumonia / Prophylaxis / Psittacosis / Pulmonary Arterial Hypertension (PAH) / Q Fever / Reflux / Relapsing Fever / Rocky Mountain Spotted Fever / Schizophrenia / Sedation / Seizures / Sepsis / Skeletal Muscle Spasms / Skin and skin-structure infections / Skin and Subcutaneous Tissue Bacterial Infections / Stable Angina (SA) / Thromboprophylaxis / Thrombotic events / Toxic effect of hydrocyanic acid and cyanides / Trachoma / Treatment-resistant Schizophrenia / Tularemia / Typhus Fever / Uncomplicated Skin and Skin Structure Infections / Uncomplicated Urinary Tract Infections / Urinary Tract Infection / Vomiting / Withdrawal1
Not AvailableCompletedNot AvailableThrombosis, Venous1
Not AvailableCompletedNot AvailableTotal Hip Arthroplasty (THA)1
Not AvailableCompletedPreventionArthroplasty, Replacement, Hip / Arthroplasty, Replacement, Knee / Hemorrhage1
Not AvailableCompletedPreventionAvascular Necrosis of Femoral Head / Degenerative Arthritis of Hip1
Not AvailableCompletedPreventionBlood Loss After Primary Total Joint Arthroplasty / Need for Blood Transfusion After Total Joint Arthroplasty1
Not AvailableCompletedPreventionBlood Platelet Disorders / Disorders, Blood Coagulation / Hematologic Diseases / Hypermenorrhea / Von Willebrand's Disease1
Not AvailableCompletedPreventionCesarean Section Complications1
Not AvailableCompletedPreventionCraniosynostosis Patients Undergoing Distraction Osteotomy1
Not AvailableCompletedPreventionIntraoperative Bleeding2
Not AvailableCompletedPreventionOsteoarthritis of the Knee1
Not AvailableCompletedTreatmentAcetabulum Fractures / Pelvic Ring Injury1
Not AvailableCompletedTreatmentAnatomic Total Shoulder Arthroplasty / Blood Loss / Reverse Total Shoulder Arthroplasty / Tranexamic Acid / Transfusions1
Not AvailableCompletedTreatmentAnterior Cruciate Ligament Reconstruction1
Not AvailableCompletedTreatmentAnterior Shoulder Instability1
Not AvailableCompletedTreatmentBlood Loss / Congenital Heart Disease (CHD)1
Not AvailableCompletedTreatmentCervical Myelopathy1
Not AvailableCompletedTreatmentChronic Hyperplastic Sinusitis / Chronic Rhinosinusitis With Polyposis1
Not AvailableCompletedTreatmentCoronary Artery Bypass Grafting (CABG) / Coronary Artery Disease (CAD)1
Not AvailableCompletedTreatmentCoronary Artery Disease (CAD)1
Not AvailableCompletedTreatmentDysplasia, Congenital Hip1
Not AvailableCompletedTreatmentHemophilia A1
Not AvailableCompletedTreatmentHemophilia / Platelet Coagulation Disorders / VonWillebrand's Disease1
Not AvailableCompletedTreatmentHemorrhage1
Not AvailableCompletedTreatmentHemorrhage / Valvular Heart Surgery1
Not AvailableCompletedTreatmentHemostasis1
Not AvailableCompletedTreatmentHypermenorrhea1
Not AvailableCompletedTreatmentKnee Arthroplasty, Total1
Not AvailableCompletedTreatmentNeurosurgery / Orthopedic Procedures / Red Blood Cells Transfusion1
Not AvailableCompletedTreatmentOff Pump Coronary Artery Bypass Surgery1
Not AvailableCompletedTreatmentOsteoarthritis (OA)1
Not AvailableCompletedTreatmentOsteoarthritis of the Knee2
Not AvailableCompletedTreatmentPost CABG Bleeding1
Not AvailableCompletedTreatmentPrimary Osteoarthritis of Knee Nos1
Not AvailableCompletedTreatmentRotator Cuff Tears / Shoulder Arthorscopy Surgery / Surgical Blood Loss / Tranexamic Acid1
Not AvailableCompletedTreatmentVaginal Bleeding During Pregnancy1
Not AvailableEnrolling by InvitationPreventionBlood Loss / Fracture Bone / General Surgery / Traumas1
Not AvailableNot Yet RecruitingNot AvailableAnkle Osteoarthritis / Bleeding / Osteoarthritis of the Knee / Tranexamic Acid1
Not AvailableNot Yet RecruitingOtherAdvanced Ovarian Cancer1
Not AvailableNot Yet RecruitingPreventionAnemia / Hip Fracture1
Not AvailableNot Yet RecruitingPreventionMyoma;Uterus / Tranexamic Acid Adverse Reaction / Uterine Leiomyomas1
Not AvailableNot Yet RecruitingTreatmentPost Inflammatory Hyperpigmentation1
Not AvailableNot Yet RecruitingTreatmentTotal Knee Arthroplasty (TKA)1
Not AvailableNot Yet RecruitingTreatmentCaudal epidural block therapy / Tranexamic Acid1
Not AvailableRecruitingNot AvailableHip Fracture1
Not AvailableRecruitingNot AvailableVon Willebrand Diseases1
Not AvailableRecruitingPreventionCesarean Section Complications6
Not AvailableRecruitingPreventionCytoreductive Surgery1
Not AvailableRecruitingPreventionHemorrhage From Placenta Previa, With Delivery1
Not AvailableRecruitingPreventionHigh Risk Pregnancies / Postpartum Haemorrhage (PPH) / Pregnancy, High-Risk / Third-Stage Postpartum Hemorrhage, With Delivery / Tranexamic Acid1
Not AvailableRecruitingPreventionPosterior Lumbar Spinal Fusion Surgery1
Not AvailableRecruitingPreventionPostpartum Haemorrhage (PPH)1
Not AvailableRecruitingTreatmentAcute Hip Fractures1
Not AvailableRecruitingTreatmentAshy Dermatosis of Ramirez / Erythema dyschromicum perstans / Lichen Planus Pigmentosus1
Not AvailableRecruitingTreatmentBlood Loss2
Not AvailableRecruitingTreatmentCalcium Nephrolithiasis / Kidney Stones1
Not AvailableRecruitingTreatmentCoagulation; Intravascular / Fibrinolysis; Hemorrhage / Rotational Thromboelastometry / Total Hip Arthroplasty (THA) / Tranexamic Acid1
Not AvailableRecruitingTreatmentEpistaxis1
Not AvailableRecruitingTreatmentGastrointestinal Bleeding1
Not AvailableRecruitingTreatmentHemorrhage1
Not AvailableRecruitingTreatmentHemostasis1
Not AvailableRecruitingTreatmentMelasma1
Not AvailableSuspendedNot AvailableMAPCA - Major Aortopulmonary Collateral Artery / Pulmonary Haemorrhage1
Not AvailableTerminatedTreatmentAnemia / Hip Fracture1
Not AvailableTerminatedTreatmentBurned / Major Surgery / Tranexamic Acid1
Not AvailableUnknown StatusPreventionAcute Aortic Dissection1
Not AvailableUnknown StatusPreventionClosed Fracture of Hip1
Not AvailableUnknown StatusPreventionNasolacrimal Tract Obstruction1
Not AvailableUnknown StatusTreatmentCardiopulmonary Bypass1
Not AvailableUnknown StatusTreatmentDeath / Hemostasis / Hexacapron / Rebleeding / Upper Gastrointestinal Hemorrhage1
Not AvailableUnknown StatusTreatmentHip Replacement Surgery / Postoperative Hemorrhages1
Not AvailableUnknown StatusTreatmentIdiopathic Scoliosis1
Not AvailableUnknown StatusTreatmentMenstrual Cycle and Uterine Bleeding Disorders1
Not AvailableWithdrawnNot AvailableCongenital Heart Disease (CHD)1
Not AvailableWithdrawnTreatmentArthroplasty, Replacement, Hip1
Not AvailableWithdrawnTreatmentChronic Rhinosinusitis1
Not AvailableWithdrawnTreatmentGastrointestinal Hemorrhage1


  • Pharmacia and upjohn co
  • Ferring pharmaceuticals as
  • Gallipot
  • Pfizer Inc.
  • Pharmacia Inc.
  • Professional Compounding Centers America LLC
  • Xanodyne Pharmaceuticals Inc.
Dosage forms
TabletOral500 mg/1
TabletOral650 mg/1
TabletOral650.0 mg
CreamTopical0.05 mg/50mL
CreamTopical0.05 g/50mL
InjectionIntravenous100 mg/1mL
Injection, solutionIntravenous1 g/10mL
Injection, solutionIntravenous100 mg/1mL
TabletOral650 1/1
Tablet, film coatedOral650 mg/1
Injection, solutionIntravenous10 mg/1mL
Unit descriptionCostUnit
Cyklokapron 100 mg/ml ampul8.8USD ml
Tranexamic acid powder1.97USD g
Cyklokapron 500 mg Tablet1.3USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patent NumberPediatric ExtensionApprovedExpires (estimated)
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more


Experimental Properties
melting point (°C)>300 °CPhysProp
water solubility1.67E+005 mg/LMERCK INDEX (1996)
logP0.3Not Available
Predicted Properties
Water Solubility18.2 mg/mLALOGPS
pKa (Strongest Acidic)4.56ChemAxon
pKa (Strongest Basic)10.22ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area63.32 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity41.9 m3·mol-1ChemAxon
Polarizability17.28 Å3ChemAxon
Number of Rings1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Human Intestinal Absorption+0.9538
Blood Brain Barrier+0.8672
Caco-2 permeable-0.8957
P-glycoprotein substrateNon-substrate0.7572
P-glycoprotein inhibitor INon-inhibitor0.9915
P-glycoprotein inhibitor IINon-inhibitor0.8475
Renal organic cation transporterNon-inhibitor0.7446
CYP450 2C9 substrateNon-substrate0.8862
CYP450 2D6 substrateNon-substrate0.7898
CYP450 3A4 substrateNon-substrate0.829
CYP450 1A2 substrateNon-inhibitor0.9504
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9577
CYP450 2C19 inhibitorNon-inhibitor0.9452
CYP450 3A4 inhibitorNon-inhibitor0.9313
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9698
Ames testNon AMES toxic0.8916
BiodegradationReady biodegradable0.6921
Rat acute toxicity1.0517 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8797
hERG inhibition (predictor II)Non-inhibitor0.9156
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)


Mass Spec (NIST)
Not Available
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available


This compound belongs to the class of organic compounds known as amino acids. These are organic compounds that contain at least one carboxyl group and one amino group.
Organic compounds
Super Class
Organic acids and derivatives
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Amino acids
Alternative Parents
Monocarboxylic acids and derivatives / Carboxylic acids / Organopnictogen compounds / Organic oxides / Monoalkylamines / Hydrocarbon derivatives / Carbonyl compounds
Amino acid / Monocarboxylic acid or derivatives / Carboxylic acid / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound / Organic oxide / Hydrocarbon derivative / Primary amine / Organooxygen compound
Molecular Framework
Aliphatic homomonocyclic compounds
External Descriptors
monocarboxylic acid (CHEBI:48669)


1. Plasminogen
Pharmacological action
General Function
Serine-type peptidase activity
Specific Function
Plasmin dissolves the fibrin of blood clots and acts as a proteolytic factor in a variety of other processes including embryonic development, tissue remodeling, tumor invasion, and inflammation. In...
Gene Name
Uniprot ID
Uniprot Name
Molecular Weight
90568.415 Da
  1. Dunn CJ, Goa KL: Tranexamic acid: a review of its use in surgery and other indications. Drugs. 1999 Jun;57(6):1005-32. [PubMed:10400410]
  2. Marti DN, Schaller J, Llinas M: Solution structure and dynamics of the plasminogen kringle 2-AMCHA complex: 3(1)-helix in homologous domains. Biochemistry. 1999 Nov 30;38(48):15741-55. [PubMed:10625440]
  3. Jansen AJ, Andreica S, Claeys M, D'Haese J, Camu F, Jochmans K: Use of tranexamic acid for an effective blood conservation strategy after total knee arthroplasty. Br J Anaesth. 1999 Oct;83(4):596-601. [PubMed:10673876]
  4. Bangert K, Thorsen S: Assay of functional plasminogen in rat plasma applicable to experimental studies of thrombolysis. Thromb Haemost. 2000 Aug;84(2):299-306. [PubMed:10959704]
  5. Hanson AJ, Quinn MT: Effect of fibrin sealant composition on human neutrophil chemotaxis. J Biomed Mater Res. 2002 Sep 5;61(3):474-81. [PubMed:12115473]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]


Pharmacological action
General Function
Peptide:proton symporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name
Uniprot ID
Uniprot Name
Solute carrier family 15 member 2
Molecular Weight
81782.77 Da
  1. Dieck ST, Heuer H, Ehrchen J, Otto C, Bauer K: The peptide transporter PepT2 is expressed in rat brain and mediates the accumulation of the fluorescent dipeptide derivative beta-Ala-Lys-Nepsilon-AMCA in astrocytes. Glia. 1999 Jan;25(1):10-20. [PubMed:9888294]

Drug created on June 13, 2005 07:24 / Updated on July 11, 2020 00:05

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.